Focused on Dx, CombiMatrix hunts for new CEO

CombiMatrix said today that it has abandoned efforts to find potential buyers of the company or its assets. Instead, the board has decided that the company will now focus its efforts on growing its diagnostics services business. "CombiMatrix has been a scientific innovator in the molecular diagnostics field, and now seeks to become a commercial leader as well," says outgoing CEO Amit Kumar in a statement. With that in mind, the board is searching for a commercially focused CEO to take Kumar's place. CombiMatrix release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.